What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature built on Fundamental Research Corp's institutional-grade valuation methodology. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is Antibe Therapeutics Inc. stock price today?

Antibe Therapeutics Inc. (ATE.TO) is currently trading at $0.295 CAD on TSX. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

What does Antibe Therapeutics Inc. do?

Antibe Therapeutics Inc. operates in the Medical - Devices sector within Healthcare. Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the Uni...

How do I analyze Antibe Therapeutics Inc. stock performance?

Our Snowflake Analysis provides a visual snapshot of Antibe Therapeutics Inc. performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find Antibe Therapeutics Inc. financial statements?

Access Antibe Therapeutics Inc. complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC applies its proprietary valuation model to public stock analysis, so fair value estimates rest on a rigorous, data-driven methodology rather than a consensus average. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About Antibe Therapeutics Inc.

Industry

Medical - Devices

Sector

Healthcare

CEO

Daniel Marcel Legault

Headquarters

Industry

Medical - Devices

Sector

Healthcare

CEO

Daniel Marcel Legault

Headquarters

Description

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

Antibe Therapeutics Inc.

ATE.TO•TSX

Antibe Therapeutics Inc.

ATE.TO•TSX

Market cap

$15.64M

Sentiment

Your view on ATE.TO

Mkt Cap

$15.64M

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

About Antibe Therapeutics Inc.

Industry: Medical - Devices
Sector: Healthcare
CEO: Daniel Marcel Legault
Headquarters: CA

Industry: Medical - Devices
Sector: Healthcare
CEO: Daniel Marcel Legault
Headquarters: CA

Description

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Antibe Therapeutics Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Antibe Therapeutics Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Antibe Therapeutics Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Antibe Therapeutics Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Antibe Therapeutics Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Antibe Therapeutics Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Antibe Therapeutics Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Antibe Therapeutics Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Antibe Therapeutics Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Antibe Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Antibe Therapeutics Inc.. Press releases and market coverage, newest first.

News

Latest Market News